Compare Stocks → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ARCTNASDAQ:CALTNASDAQ:CARANASDAQ:CMPSNASDAQ:IMGO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$26.17-3.0%$33.94$17.52▼$43.81$726.17M2.6465,675 shs526,939 shsCALTCalliditas Therapeutics AB (publ)$19.20+3.8%$20.89$15.25▼$29.30$551.12M1.55,347 shs5,994 shsCARACara Therapeutics$0.70+4.5%$0.83$0.50▼$4.67$36.71M0.7344,920 shs318,977 shsCMPSCOMPASS Pathways$7.86-3.0%$9.73$5.01▼$12.75$501.74M2.48677,678 shs1.49 million shsIMGOImago BioSciences$36.01$35.96$11.56▼$36.09$1.22B2.82171,367 shsN/A10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics-3.00%-0.57%-18.55%-17.50%-1.80%CALTCalliditas Therapeutics AB (publ)+3.78%+8.78%-9.77%-16.49%-21.18%CARACara Therapeutics+4.23%+1.45%-4.14%+21.42%-82.50%CMPSCOMPASS Pathways-2.96%-6.65%-15.57%-26.47%-3.79%IMGOImago BioSciences0.00%0.00%0.00%0.00%0.00%World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARCTArcturus Therapeutics2.5831 of 5 stars3.52.00.00.02.23.30.6CALTCalliditas Therapeutics AB (publ)2.1937 of 5 stars3.33.00.00.01.70.01.9CARACara Therapeutics3.6939 of 5 stars3.41.00.04.21.21.71.3CMPSCOMPASS Pathways1.2916 of 5 stars3.51.00.00.02.41.70.0IMGOImago BioSciencesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics3.00Buy$61.33134.37% UpsideCALTCalliditas Therapeutics AB (publ)2.50Moderate Buy$34.0077.08% UpsideCARACara Therapeutics2.75Moderate Buy$9.751,292.86% UpsideCMPSCOMPASS Pathways3.00Buy$47.40503.05% UpsideIMGOImago BioSciencesN/AN/AN/AN/ACurrent Analyst RatingsLatest ARCT, CARA, CALT, IMGO, and CMPS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024CMPSCOMPASS PathwaysCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight4/10/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.004/1/2024CMPSCOMPASS PathwaysMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$30.003/28/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/20/2024ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.003/8/2024ARCTArcturus TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/6/2024CARACara TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.003/5/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/1/2024CMPSCOMPASS PathwaysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$120.002/22/2024CALTCalliditas Therapeutics AB (publ)HC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.002/8/2024ARCTArcturus TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $48.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$169.93M4.15N/AN/A$10.42 per share2.51CALTCalliditas Therapeutics AB (publ)$113.78M5.03N/AN/A$1.06 per share18.11CARACara Therapeutics$20.97M1.82N/AN/A$1.05 per share0.67CMPSCOMPASS PathwaysN/AN/AN/AN/A$3.65 per shareN/AIMGOImago BioSciencesN/AN/AN/AN/A$6.40 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$29.73M-$1.04N/A9.91N/A-15.65%-18.22%-11.95%5/14/2024 (Estimated)CALTCalliditas Therapeutics AB (publ)-$43.96M-$1.64N/A5.57N/A-38.72%-104.47%-26.75%5/21/2024 (Estimated)CARACara Therapeutics-$118.51M-$2.18N/AN/AN/A-565.21%-122.10%-89.64%5/20/2024 (Estimated)CMPSCOMPASS Pathways-$118.46M-$2.39N/AN/AN/AN/A-58.72%-49.46%5/9/2024 (Estimated)IMGOImago BioSciences-$42.31M-$1.84N/AN/AN/AN/A-31.85%-30.07%N/ALatest ARCT, CARA, CALT, IMGO, and CMPS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023ARCTArcturus Therapeutics-$1.69-$0.32+$1.37-$0.32$64.14 million$33.99 million3/4/202412/31/2023CARACara Therapeutics-$0.57-$0.59-$0.02-$0.59$2.34 million$3.00 million 2/29/2024Q4 2023CMPSCOMPASS Pathways-$0.37-$0.53-$0.16-$0.53N/AN/A2/21/202412/31/2023CALTCalliditas Therapeutics AB (publ)-$0.09-$0.07+$0.02-$0.06$36.24 million$42.45 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus TherapeuticsN/AN/AN/AN/AN/ACALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/ACARACara TherapeuticsN/AN/AN/AN/AN/ACMPSCOMPASS PathwaysN/AN/AN/AN/AN/AIMGOImago BioSciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus TherapeuticsN/A4.724.72CALTCalliditas Therapeutics AB (publ)2.893.133.08CARACara TherapeuticsN/A4.544.43CMPSCOMPASS Pathways0.1413.3313.33IMGOImago BioSciencesN/A13.1513.16OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%CALTCalliditas Therapeutics AB (publ)2.83%CARACara Therapeutics44.66%CMPSCOMPASS Pathways46.19%IMGOImago BioSciences91.53%Insider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics13.80%CALTCalliditas Therapeutics AB (publ)2.20%CARACara Therapeutics4.20%CMPSCOMPASS Pathways4.25%IMGOImago BioSciences14.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18026.92 million23.20 millionOptionableCALTCalliditas Therapeutics AB (publ)19229.79 million29.14 millionOptionableCARACara Therapeutics5554.67 million52.37 millionOptionableCMPSCOMPASS Pathways18661.94 million59.31 millionOptionableIMGOImago BioSciences2733.82 million28.78 millionNot OptionableARCT, CARA, CALT, IMGO, and CMPS HeadlinesSourceHeadlineBuffoonery abounds in Imago Theatre’s deep-thinking ‘Mission Gibbons’oregonlive.com - April 16 at 4:14 PMImago Theatre aims to find out if time-traveling Neanderthals have answers to climate changemsn.com - April 13 at 2:54 PMMerck: Better Times Ahead On Approvals And Outlookseekingalpha.com - April 2 at 5:48 PMClarus Lifesciences III, L.P.'s Net Worthbenzinga.com - February 23 at 3:04 PMAnixa Biosciences Inc ANIXmorningstar.com - December 21 at 10:46 PMImago DEI Programbc.edu - December 19 at 1:47 PMMerck bulks up in haematology, buying Imago for $1.35bnpharmaphorum.com - May 21 at 3:52 PMProfessor Sherif El-Khamisysheffield.ac.uk - April 6 at 9:17 AMHarmony Biosciences shares are trading lower after the company reported Q4 financial results.benzinga.com - February 23 at 9:00 PMToday Storiespharmiweb.com - January 18 at 7:36 AMMerck completes $1.35 billion purchase of Imago, developer of medicine for bone-marrow diseaseswfmz.com - January 11 at 8:02 PMMerck To Complete Acquisition Of Imagomarkets.businessinsider.com - January 11 at 10:01 AMMerck Completes Tender Offer to Acquire Imago BioSciences, Inc.finance.yahoo.com - January 11 at 10:01 AMLooking Into Imago BioSciences's Recent Short Interestmsn.com - January 4 at 3:22 PMMerck is best performing large U.S. pharma of 2022seekingalpha.com - December 30 at 1:33 PMImago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosisfinance.yahoo.com - December 20 at 6:26 PMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ELVT, IMGO, GRAY, USERmarkets.businessinsider.com - December 13 at 3:25 PMImago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022finance.yahoo.com - December 12 at 5:17 PMImago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2022finance.yahoo.com - December 12 at 5:17 PMMerck Commences Tender Offer To Acquire Imago BioSciencesmarkets.businessinsider.com - December 12 at 7:39 AMHow Is The Market Feeling About Imago BioSciences?msn.com - December 9 at 4:41 PMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPNT, IMGO, SALbakersfield.com - December 8 at 3:43 AMImago BioSciences: The Bone Marrow Cancer Researcher Reaches Milestoneseekingalpha.com - November 30 at 9:36 PMImago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemiafinance.yahoo.com - November 30 at 9:36 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsArcturus TherapeuticsNASDAQ:ARCTArcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Calliditas Therapeutics AB (publ)NASDAQ:CALTCalliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was founded in 2004 and is headquartered in Stockholm, Sweden.Cara TherapeuticsNASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.COMPASS PathwaysNASDAQ:CMPSCOMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Imago BioSciencesNASDAQ:IMGOImago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.